Chinanews.com, Beijing, November 11 (Wei Xianghui) Winter respiratory diseases have entered a period of high incidence, and the demand for corresponding treatment drugs has continued to increase, and various "Internet celebrity prescriptions" have also emerged in an endless stream. Doctors suggest that there are individual differences in medication, and if conditions permit, especially in children with fever, the medication should first go to the hospital to detect which pathogen is causing it, and cannot be used blindly.
Does oseltamivir protect against the flu?
According to CCTV financial reports, data from online platforms show that the overall demand for drugs for respiratory tract infections in Beijing has continued to rise since the beginning of autumn. Among them, oseltamivir sales increased by more than 1.6 times month-on-month.
Professor Zhang Jiming, deputy director of the Department of Infectious Diseases of Huashan Hospital Affiliated to Fudan University, told Chinanews that oseltamivir is currently one of the main drugs for the treatment of influenza virus, but not everyone who has influenza should use oseltamivir, let alone use it as a routine to prevent influenza.
Zhang Jiming explained that oseltamivir is a specific neuraminidase inhibitor, which has a strong and selective competitive inhibitory effect on influenza virus neuraminidase, which can effectively inhibit the release of influenza virus from infected cells and reduce the spread of influenza virus in the body, thereby playing a role in the treatment of influenza A and B.
In other words, the main role of oseltamivir is to stop the spread of the virus, not to stop the virus from entering. Therefore, for normal people who are not infected with the influenza virus, taking oseltamivir does not prevent viral infection. Currently, vaccination remains the most effective form of prevention against influenza.
Zhang Jiming said that in addition to oseltamivir, Sufuda is also a commonly used drug for influenza, but both are prescription drugs and have certain side effects, which need to be used under the guidance of a doctor, and cannot be used blindly.
Screenshot from e-commerce platform
Is the mycoplasma "three-piece set" reliable?
This year, there is a high incidence of Mycoplasma pneumoniae infection, and "azithromycin + ibuprofen + methanamine healin" has become a "three-piece set" of Internet celebrity medication circulating on social media.
Zhang Jiming reminded that the so-called "Internet celebrity prescription" can not be easily believed, and the drug will show individual differences in patients, especially for children, in the case of imperfect functional development of multiple organs, the treatment of drugs needs to be combined with the child's own basic condition, evaluated by the doctor, so as to give safe and effective suggestions.
Zhang Jiming provided a copy of this year's "Notice on Adjusting the Diagnosis and Treatment Plan for Mycoplasma pneumoniae" of the Children's Hospital Affiliated to Fudan University this year. From the perspective of clinical work, the number of cases of mycoplasma pneumonia is large, and many children still have persistent high fever or lobar or multiple segmental consolidation in the lobules of the lungs after routine use of the first-line drug azithromycin for many days, and the positive rate of clinical mycoplasma drug resistance gene detection is high, and the response to conventional macrolide antibiotic treatment is poor.
The adjusted regimen showed that after 3 days of conventional drug treatment, the condition did not improve, and the second-line drugs were started according to age, including doxycycline for those over 8 years old and moxifloxacin for children under 8 years old, but before use, it was necessary to explain to the family of the child and obtain informed consent from the family of the child.
Zhang Jiming said that early differential diagnosis is very important, and now the general clinic of the hospital can detect influenza virus, new coronavirus, mycoplasma, etc., and after finding out the cause, targeted treatment can be carried out in time. Except for a small number of patients with drug resistance, most patients with Mycoplasma pneumoniae infection have obvious drug effects.
The picture comes from the Children's Hospital of Fudan University, "Notice on Adjusting the Diagnosis and Treatment Plan for Mycoplasma Pneumoniae Pneumoniae"
There is no specific drug for respiratory syncytial virus
Recently, the epidemic intensity of RSV has increased. On November 11, Wang Quanyi, deputy director of the Beijing Center for Disease Control and Prevention and chief epidemiologist, introduced that from the outpatient visits of children's hospitals and pediatric research institutes, the current epidemic intensity of Mycoplasma pneumoniae has dropped to the fourth place in children's respiratory infectious diseases, and the top three are influenza, adenovirus, and respiratory syncytial virus. In addition, according to the results of respiratory pathogenic surveillance, the top three reported cases of respiratory infectious diseases in the whole population of the city are: influenza, rhinovirus, and respiratory syncytial virus.
According to Zhang Jiming, respiratory syncytial virus infection is a self-limiting disease, which is generally mild and can be recovered in 1-2 weeks. However, the virus still poses a great threat to infants under 6 months old, the elderly and immunocompromised people, and is the primary factor causing hospitalization of infants and young children with viral respiratory infections.
At present, there is no specific antiviral treatment for respiratory syncytial virus infection, and vaccines and prophylactic monoclonal antibodies have been approved for use abroad, but have not been approved for marketing in China. Children with mild symptoms can rest at home, but if they have symptoms such as persistent cough, shortness of breath and difficulty breathing, they should seek medical attention promptly. (ENDS)